Core Points - Yifan Pharmaceutical (002019) responded to investor inquiries on October 24, detailing the milestone payments for Yilishu in the U.S. market, which include upfront payments, milestone payments upon product launch, and sales milestone payments [1] - The revenue from Yilishu encompasses shipping revenue and sales sharing payments [1]

证券日报网讯亿帆医药（002019）10月24日在互动平台回答投资者提问时表示，截至2025年10月20日公 司股东人数为47，150户。 ...

Core Viewpoint - Yifan Pharmaceutical stated on October 24 that it will fulfill its information disclosure obligations in a timely manner in accordance with relevant regulations if there are any significant matters [2] Company Summary - Yifan Pharmaceutical responded to investor inquiries on an interactive platform regarding its commitment to timely information disclosure [2]

Core Viewpoint - Yifan Pharmaceutical stated that its production and operations are currently normal, and it adheres strictly to legal regulations and disclosure requirements, with no undisclosed significant matters or premature performance leaks [1] Group 1 - The company confirmed that it is operating normally and in compliance with relevant laws and regulations [1] - There are no significant matters that should have been disclosed but were not [1] - The company denied any incidents of performance information being leaked in advance [1]

Core Viewpoint - Yifan Pharmaceutical (002019) emphasizes its commitment to sustainable development, focusing on environmental protection, social responsibility, and corporate governance [1] Group 1 - The company has consistently prioritized sustainable development [1] - The company values environmental protection as part of its operational strategy [1] - The company is dedicated to fulfilling its social responsibilities [1]

Core Viewpoint - Yifan Pharmaceutical (002019) remains focused on its core business development and reports that operations are running smoothly, with management expressing confidence in future growth [1] Company Summary - The company is actively engaging with investors through interactive platforms, indicating a commitment to transparency and communication [1] - Management's confidence suggests a positive outlook for the company's strategic direction and operational performance [1]

Core Viewpoint - Recently, there have been no on-site research activities conducted by institutional investors for Yifan Pharmaceutical (002019.SZ) [1] Company Summary - Yifan Pharmaceutical confirmed on October 22 that there have been no recent on-site research activities by institutional investors [1]

Core Viewpoint - The company has not yet received feedback from its exclusive U.S. distributor regarding the sales performance of F627 in the third quarter [1] Group 1 - An investor inquired about the sales situation of F627 in the U.S. and whether it met or exceeded expectations [1] - The company expressed gratitude for the inquiry and confirmed the lack of feedback from its partner [1]

Core Viewpoint - Yifan Pharmaceutical's stock has shown a year-to-date increase of 31.64%, with recent fluctuations indicating a slight decline over the past 20 and 60 days, suggesting potential volatility in the near term [1][2]. Financial Performance - For the first half of 2025, Yifan Pharmaceutical reported a revenue of 2.635 billion yuan, reflecting a year-on-year growth of 0.11%, while the net profit attributable to shareholders was 304 million yuan, marking a significant increase of 19.91% [2]. - Cumulatively, since its A-share listing, Yifan Pharmaceutical has distributed a total of 1.328 billion yuan in dividends, with 243 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Yifan Pharmaceutical stood at 46,600, a decrease of 0.46% from the previous period, while the average number of circulating shares per person increased by 0.46% to 18,048 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 25.5819 million shares, which is an increase of 2.4783 million shares compared to the previous period [3]. Stock Performance - As of October 15, Yifan Pharmaceutical's stock price was 13.98 yuan per share, with a trading volume of 53.7966 million yuan and a turnover rate of 0.46%, resulting in a total market capitalization of 17.005 billion yuan [1]. - The stock has experienced a net inflow of main funds amounting to 5.0723 million yuan, with significant buying and selling activity from large orders [1].

Core Viewpoint - The transaction between Fangsheng Pharmaceutical and Yifan Pharmaceutical involves the acquisition of the marketing authorization for "Compound Dexamethasone Acetate Cream," which is expected to enhance the company's product portfolio in dermatology and potentially serve as a new profit growth point [1] Group 1: Transaction Details - The contract was signed on September 30, 2025, and does not constitute a related party transaction or a major asset restructuring, falling within the chairman's approval authority [1] - The payment for the transaction will be made in three phases, indicating a structured financial approach to the acquisition [1] Group 2: Market Context - The drug is used for various skin diseases, with 103 companies in China holding production licenses for it [1] - In the first half of 2025, the sales revenue from physical pharmacies for this drug reached 175 million yuan, highlighting its market potential [1] Group 3: Strategic Implications - The acquisition aligns with the company's development strategy to expand its dermatological product offerings, which is expected to contribute positively to future revenue streams [1] - However, the timeline for completing the holder change procedures remains uncertain, and sales may be influenced by market factors, necessitating cautious decision-making by investors [1]